BORON NEUTRON
CAPTURE THERAPY (BNCT)

BNCT exploits a fundamental nuclear reaction to destroy cancer cells with extraordinary selectivity — introducing a biological layer of targeting that conventional radiotherapy cannot achieve.

“BNCT does not aim radiation at cancer — it loads cancer cells with the means of their own destruction, then triggers it.”

• How It Differs from Conventional Radiotherapy

  Conventional X-rays and protons damage DNA along the beam path — in cancer and healthy cells alike. BNCT delivers lethal nuclear energy only inside cells that have absorbed boron-10, confining destruction to approximately one cell diameter.

• The Two Key Ingredients

  First: a boron-containing drug (BPA) that accumulates preferentially in cancer cells. Second: a neutron beam directed at the tumour. When thermal neutrons are captured by boron-10 atoms inside cancer cells, a nuclear reaction releases alpha particles — lethal to that single cell.

• From Reactor to Hospital

  BNCT was first proposed in the 1930s. Japan's 2020 PMDA approval of accelerator-based BNCT (Sumitomo system + borofalan) for recurrent head and neck cancer marked the transition from nuclear facility to hospital-based treatment — transforming BNCT from research to clinical practice.

• Reactor-Based vs Accelerator-Based

  Early BNCT required nuclear reactors (Japan, Finland, Netherlands). Modern accelerator-based BNCT (AB-BNCT) uses a compact proton/deuteron accelerator installed within a hospital — no reactor licence required, operable like a conventional linac.

BNCT is a multi-stage biological and physical process. Each step must succeed for treatment to be effective.

1. 1

   BPA Infusion

   Boronophenylalanine (BPA) is infused IV over 1–2 hours. Cancer cells — with elevated LAT1 amino acid transporter expression — preferentially absorb BPA, accumulating boron-10 at concentrations significantly higher than in normal tissue.

2. 2

   18F-BPA-PET Imaging

   PET-CT using 18F-labelled BPA confirms and maps boron uptake within the tumour. The tumour-to-normal tissue ratio (T/N ratio) is calculated. This is a mandatory go/no-go eligibility gate — insufficient uptake means BNCT is not suitable.

3. 3

   Neutron Irradiation

   The tumour area is irradiated with epithermal neutrons (for deep tumours) or thermal neutrons. The irradiation session lasts 30–60 minutes per fraction. The neutron beam itself causes minimal direct tissue damage.

4. 4

   Nuclear Capture Reaction

   10B + neutron → alpha particle (4He) + lithium-7 ion + 2.79 MeV energy. The alpha particle and Li-7 ion travel only ~10 µm in tissue — one cell diameter. Lethal energy is confined almost entirely to boron-loaded tumour cells.

5. 5

   Tumour Response

   High-LET alpha particle damage causes irreparable DNA double-strand breaks in tumour cells. Unlike X-ray damage, this is largely non-reparable. Tumour regression develops over weeks to months as damaged cells die.

BNCT selectivity depends almost entirely on how preferentially boron accumulates in cancer cells. Two compounds have been used clinically; a new generation is in active development.

China has emerged as one of the world's most significant investors in BNCT infrastructure — driven by high head and neck cancer burden, strategic medtech investment, and a large international patient population.

“Xiamen Humanity Hospital operates China's first systematic AB-BNCT clinical programme using the same Sumitomo technology platform that underpins Japan's approved treatment.”

• Xiamen Humanity Hospital

  First mainland Chinese hospital to commission an accelerator-based BNCT system (Sumitomo Heavy Industries). Operates under a clinical research framework for recurrent H&N cancers with systematic outcome tracking aligned to the Japanese STELLA trial protocol.

• NMPA Regulatory Pathway

  China's NMPA is developing a BNCT approval framework encompassing both the neutron source device and boron pharmaceutical, drawing on Japan's PMDA approval data and China's emerging clinical experience.

• Academic Research Programme

  Peking University, Fudan University, and CNNC-affiliated nuclear physics institutes are conducting preclinical research on next-generation boron agents, computational dosimetry, and BNCT–immunotherapy combinations.

• Why Patients Choose China

  Geographic accessibility from South Asia, SE Asia, and the Middle East; significantly lower cost than Japan; CancerFax navigation support; and opportunities to combine BNCT with other advanced therapies (CAR-T, clinical trials) at major Chinese centres.

Head and neck squamous cell carcinoma (recurrent after prior radiotherapy) is the only approved BNCT indication. Glioblastoma is the most studied emerging indication.

• Head and Neck Cancer — The Approved Indication

  Recurrent H&N squamous cell carcinoma after prior radiotherapy is BNCT's primary target. High LAT1 expression ensures reliable BPA uptake; proximity to critical structures limits conventional re-irradiation; and BNCT's cell-level selectivity allows tumour irradiation with substantially lower dose to adjacent spinal cord, brainstem, and salivary glands. The STELLA trial demonstrated >60% objective response rate.

• Nasopharyngeal Carcinoma (NPC)

  NPC has unusually high incidence in southern China, SE Asia, and the Middle East — precisely the populations CancerFax serves. Recurrent NPC after chemoradiation is surrounded by critical structures that severely limit re-irradiation options. BNCT is an active area of Chinese clinical investigation for this indication.

• Glioblastoma (GBM)

  GBM's infiltrative growth — cells migrating far beyond visible MRI margins — makes it conceptually ideal for BNCT, which targets boron-loaded cells regardless of imaging visibility. Japanese reactor-based series reported median OS of 15–27 months vs 14–16 months with standard Stupp protocol. AB-BNCT GBM programmes are generating updated data in Japan, Taiwan, and China.

• Radioresistant and Recurrent Cancers

  BNCT's alpha particles are high-LET — they kill cells through direct DNA damage independent of oxygen. Hypoxic tumour cells (2.5–3× more resistant to conventional X-rays) are equally susceptible to BNCT. This makes BNCT effective where conventional re-irradiation cannot safely proceed and where tumour hypoxia has driven radioresistance.

Data from the STELLA trial (Japan) and historical reactor-based GBM programmes establish the efficacy foundation for BNCT.

• >60%Objective Response Rate (STELLA)Recurrent H&N SCC — basis for Japan PMDA 2020 approval.
• 15–27 moMedian OS — GBM (Reactor Series)vs 14–16 months with standard Stupp chemoradiation.
• 60–80%Pain Relief — Bone MetsPalliative radiation response rate for bone metastases from BNCT programmes.
• 2020Japan PMDA Approval YearFirst regulatory approval of an accelerator-based BNCT system globally.
• 72%Complete response rate in laryngeal and pharyngeal recurrence after BNCTA 2024 follow-up analysis from the JHN002 program reported a 72% complete response rate, showing that BNCT can produce not just tumor shrinkage, but full radiologic disappearance in selected recurrent head and neck cases.
• 1–2Fractions in most modern BNCT treatment protocolsUnlike prolonged conventional radiotherapy courses, BNCT is typically completed in just one or two treatment sessions.

AB-BNCT systems are enabling exploration of BNCT across cancer types where biology favours boron uptake or where existing treatment options are insufficient.

BNCT candidacy is determined by a structured eligibility process. The 18F-BPA-PET scan is the single most critical gate.

BNCT is positioned within multimodal treatment strategies — not used in isolation.

• BNCT + Surgery

  Surgical debulking before BNCT reduces cancer cell volume, improving probability of complete elimination. For GBM: maximum safe resection addresses bulk disease, then BNCT targets diffusely infiltrating cells surgery cannot reach.

• BNCT + Chemotherapy

  EGFR inhibitors (gefitinib, erlotinib) upregulate LAT1 in preclinical models — potentially increasing BPA uptake and boron concentration at the tumour. Temozolomide + BNCT combination is under investigation for GBM.

• BNCT + Immunotherapy

  BNCT's high-LET alpha particles induce immunogenic tumour cell death — potentially triggering systemic anti-tumour immunity and abscopal effects. Combination with PD-1/PD-L1 checkpoint inhibitors is under preclinical evaluation.

• BNCT vs Conventional Re-Irradiation

  When normal tissue has already received prior radiation, BNCT delivers significantly lower additional dose to healthy structures compared to conventional re-irradiation. Studies show lower rates of serious complications — particularly mandibular osteoradionecrosis and soft tissue necrosis.

From initial report review to post-treatment follow-up — a structured, multi-step process over approximately 2–4 weeks in-country.

1. 1

   Medical Report Review & Pre-Screening

   Pathology, prior treatment records, current imaging, and molecular results reviewed remotely by the BNCT team. CancerFax coordinates submission and translation. Go/no-go for travel based on preliminary eligibility assessment.

2. 2

   18F-BPA-PET Imaging

   BPA infused IV over 1–2 hours at the BNCT centre, followed by PET-CT. The tumour T/N ratio is calculated. This is the definitive eligibility gate — patients with insufficient uptake are redirected to alternative treatments.

3. 3

   MDT Review & Treatment Planning

   3D neutron transport simulations calculate boron and neutron dose distribution throughout the treatment volume. Dosimetry confirms that the tumour will receive a lethal dose and that critical structures remain within tolerance.

4. 4

   BPA Infusion + Neutron Irradiation

   Therapeutic BPA dose infused IV over 1–2 hours. Blood samples taken for real-time plasma boron measurement and dosimetric refinement. Patient positioned at neutron aperture; irradiation lasts 30–60 minutes per fraction.

5. 5

   Observation, Discharge & Follow-Up

   Observation for acute reactions (erythema, fatigue, mucositis in H&N cases) for several hours to overnight before discharge. Imaging review at 1, 3, and 6 months to assess tumour response and monitor for late toxicity.

BNCT's toxicity profile differs meaningfully from conventional radiotherapy — but is not absent. Understanding what to expect enables prompt management.

Approximate estimates only. Actual costs depend on clinical programme, fractions required, hospital stay, and individual clinical needs. Obtain a personalised estimate before committing to travel.

Explore these in-depth guides on related treatments, therapies, and cancer care topics.

Frequently Asked Questions